CN103442709B - 减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物 - Google Patents

减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物 Download PDF

Info

Publication number
CN103442709B
CN103442709B CN201180069476.5A CN201180069476A CN103442709B CN 103442709 B CN103442709 B CN 103442709B CN 201180069476 A CN201180069476 A CN 201180069476A CN 103442709 B CN103442709 B CN 103442709B
Authority
CN
China
Prior art keywords
liver
improving
pharmaceutical composition
bel
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180069476.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103442709A (zh
Inventor
张秀凤
马俊贤
杨国义
林士弘
林坚栋
黄凯文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belks Biotechnology Co ltd
Original Assignee
Industrial Technology Research Institute ITRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Technology Research Institute ITRI filed Critical Industrial Technology Research Institute ITRI
Publication of CN103442709A publication Critical patent/CN103442709A/zh
Application granted granted Critical
Publication of CN103442709B publication Critical patent/CN103442709B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201180069476.5A 2011-03-22 2011-03-22 减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物 Active CN103442709B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/072045 WO2012126178A2 (zh) 2011-03-22 2011-03-22 减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物

Publications (2)

Publication Number Publication Date
CN103442709A CN103442709A (zh) 2013-12-11
CN103442709B true CN103442709B (zh) 2018-10-19

Family

ID=46879777

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180069476.5A Active CN103442709B (zh) 2011-03-22 2011-03-22 减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物

Country Status (13)

Country Link
EP (1) EP2689777B1 (enExample)
JP (1) JP6166251B2 (enExample)
KR (2) KR101981378B1 (enExample)
CN (1) CN103442709B (enExample)
AU (1) AU2011362905B2 (enExample)
CA (1) CA2830616C (enExample)
DK (1) DK2689777T3 (enExample)
ES (1) ES2668785T3 (enExample)
NO (1) NO2689777T3 (enExample)
PL (1) PL2689777T3 (enExample)
RU (1) RU2561688C2 (enExample)
SG (1) SG193486A1 (enExample)
WO (1) WO2012126178A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114712386A (zh) * 2021-03-31 2022-07-08 贝尔克斯生技股份有限公司 高聚原花青素组合物及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179774A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
CN104774909A (zh) * 2014-10-17 2015-07-15 江苏大学 一种原花青素诱导肝癌细胞自噬性死亡的分析方法及应用
GB201909709D0 (en) * 2019-07-05 2019-08-21 Univ Liverpool Biomarkers for irritable bowel syndrome
WO2022080846A1 (ko) * 2020-10-13 2022-04-21 서울대학교병원 플라본을 포함하는 섬유증의 예방 또는 치료용 조성물
CN115010720B (zh) * 2022-06-02 2023-08-11 中国科学院昆明植物研究所 中甸艾中倍半萜二聚体及其药物组合物与其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1443533A (zh) * 2002-03-07 2003-09-24 程彦杰 原花青素类化合物在用于制备解酒保肝产品方面的用途
CN1933818A (zh) * 2004-01-30 2007-03-21 马尔斯公司 用于治疗癌症的方法和组合物
JP2009242374A (ja) * 2008-03-14 2009-10-22 Miyazakiken Sangyo Shien Zaidan 肝線維化抑制剤
CN101822372A (zh) * 2009-03-05 2010-09-08 财团法人工业技术研究院 用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
TW200505468A (en) * 2003-08-11 2005-02-16 Suntory Ltd Agent for improving hepato-bililary dysfunction
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
JP2008156265A (ja) * 2006-12-22 2008-07-10 Yamagata Prefecture Ａ型プロアントシアニジンオリゴマー画分及びその製造方法
JP2008195672A (ja) * 2007-02-14 2008-08-28 Okayama Univ 経口摂取用組成物及び経口摂取用組成物の製造方法
TWI370736B (en) * 2008-12-31 2012-08-21 Ind Tech Res Inst Pharmaceutical composition for treating hepatitis b and heath food for inhibiting hepatitis b virus
CN101507730B (zh) * 2009-03-26 2011-01-26 复旦大学 表没食子儿茶素没食子酸酯与柔红霉素的组合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1443533A (zh) * 2002-03-07 2003-09-24 程彦杰 原花青素类化合物在用于制备解酒保肝产品方面的用途
CN1933818A (zh) * 2004-01-30 2007-03-21 马尔斯公司 用于治疗癌症的方法和组合物
JP2009242374A (ja) * 2008-03-14 2009-10-22 Miyazakiken Sangyo Shien Zaidan 肝線維化抑制剤
CN101822372A (zh) * 2009-03-05 2010-09-08 财团法人工业技术研究院 用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114712386A (zh) * 2021-03-31 2022-07-08 贝尔克斯生技股份有限公司 高聚原花青素组合物及其应用
WO2022205137A1 (zh) * 2021-03-31 2022-10-06 贝尔克斯生技股份有限公司 高聚原花青素组合物及其应用
TWI807738B (zh) 2021-03-31 2023-07-01 貝爾克斯生技股份有限公司 高聚原花青素組合物及其應用

Also Published As

Publication number Publication date
PL2689777T3 (pl) 2018-08-31
CN103442709A (zh) 2013-12-11
JP2014508785A (ja) 2014-04-10
WO2012126178A3 (zh) 2012-11-22
RU2013146602A (ru) 2015-04-27
KR101981378B1 (ko) 2019-05-22
ES2668785T3 (es) 2018-05-22
AU2011362905B2 (en) 2015-11-12
KR20140020966A (ko) 2014-02-19
KR20160143868A (ko) 2016-12-14
CA2830616C (en) 2017-02-21
CA2830616A1 (en) 2012-09-27
DK2689777T3 (en) 2018-05-22
EP2689777A4 (en) 2014-09-17
EP2689777A2 (en) 2014-01-29
NO2689777T3 (enExample) 2018-08-25
AU2011362905A1 (en) 2013-10-31
WO2012126178A2 (zh) 2012-09-27
RU2561688C2 (ru) 2015-08-27
JP6166251B2 (ja) 2017-07-19
SG193486A1 (en) 2013-10-30
EP2689777B1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
Cheng et al. Mulberry fruits extracts induce apoptosis and autophagy of liver cancer cell and prevent hepatocarcinogenesis in vivo
CN103442709B (zh) 减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物
CN101485655B (zh) 二氢杨梅素在制备防治肿瘤放化疗不良反应的药物的应用
RU2700793C2 (ru) Фармацевтическая композиция, содержащая силибин, витамин е и l-карнитин
Wang et al. E Se tea extract ameliorates CCl4 induced liver fibrosis via regulating Nrf2/NF-κB/TGF-β1/Smad pathway
Abdo et al. Calligonum comosum extract inhibits diethylnitrosamine-induced hepatocarcinogenesis in rats
US20100168221A1 (en) Pharmaceutical composition for treating hepatitis b virus and health food product having hepatitis b virus inhibiting effects
Sun et al. The phenolic profiles of Radix Tetrastigma after solid phase extraction (SPE) and their antitumor effects and antioxidant activities in H22 tumor-bearing mice
JP2007145849A (ja) Ｓｏｌａｎｕｍ属の植物由来の水溶性抽出物およびそれらの調製方法、ならびに水溶性抽出物を含む薬学的組成物
Gao et al. Protective effect of the combinations of glycyrrhizic, ferulic and cinnamic acid pretreatment on myocardial ischemia-reperfusion injury in rats
CN104027362B (zh) 用于治疗肺癌的牛樟芝萃取物及其制备方法
Li et al. Codonopis bulleynana Forest ex Diels (cbFeD) effectively attenuates hepatic fibrosis in CCl4-induced fibrotic mice model
Pradhan et al. Cardioprotective effects of Rhododendron arboreum leaf extract against Doxorubicin-induced cardiotoxicity in Wistar rats by modulating electrocardiographic and cardiac biomarkers
TWI458487B (zh) 藥學組合物之用途
HK1188720B (zh) 减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物
CN110420247A (zh) 珠芽蓼提取物及其制备方法和应用
CN104096150B (zh) 姜叶三七及其提取物在制备治疗和/或预防癌症药物的应用
CN103709015B (zh) 银杏酚c17:1在肝癌治疗中的用途
TWI807738B (zh) 高聚原花青素組合物及其應用
WO2012005581A1 (en) Xanthanodien for the treatment of cancer
Albayrak et al. Hepatoprotective potential of solvent-derived artichoke leaf extracts against cyclophosphamide-induced liver injury in rat model
Elgendy et al. The potential therapeutic effect of Luteolin against Diethyl nitrosamine induced hepatocellular carcinoma in rats.
CN108721272A (zh) 一种新型抗纤维化药物及动物模型的构建方法
Wang et al. Potential new drug sources for the treatment of Parkinson’s disease: flavonoid O-glycosides
Ghaffar et al. The hematological and histological studies for the hepatoprotective-like effect of the hydromethanolic extract and the fractions of Viola serpens Wall.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1188720

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20221122

Address after: Taiwan, Taipei, China

Patentee after: Belks Biotechnology Co.,Ltd.

Address before: Hsinchu County, Taiwan, China

Patentee before: Industrial Technology Research Institute

TR01 Transfer of patent right